CleanSpace Holdings Limited (ASX: $CSX) announces a (unaudited) sales update as at 30 June 2024. The company reported preliminary revenue results for the year ended 30 June 2024 (FY24) with sales of $15.7M, marking a 30% growth versus the previous corresponding period (PCP) and a 33% growth in the second half of the year (H2) (unaudited results). CleanSpace has been maintaining strong sales momentum over the last 18 months, meeting the Company's core objective of ongoing 30% annual revenue growth. Revenue has shown sequential growth over the last 4 half year periods, with around 97% of the Company's revenue derived from Industrial sectors in FY24, signifying a shift in focus from healthcare markets since FY22.
The ongoing 30% annual revenue growth demonstrates our commitment to delivering value to our stakeholders. We are pleased with the strong sales momentum and the positive revenue growth in Europe, Asia Pacific, and North America regions in H2. The successful launch of CleanSpace WORK in Europe and Australia has been a key driver of our growth in FY24, catering to small businesses, tradespeople, and workers facing respiratory risks while maintaining the highest level of respiratory protection. We are excited about the upcoming detailed, audited full year FY24 results and look forward to sharing them with our stakeholders on 27 August 2024.
CleanSpace Holdings Limited (ASX: $CSX) has reported a strong sales performance for FY24, with a 30% growth versus the previous corresponding period (PCP) and a 33% growth in the second half of the year (H2) (unaudited results). The Company's focus on industrial sectors has been evident, with around 97% of the revenue derived from these sectors in FY24. The successful launch of CleanSpace WORK in Europe and Australia has contributed significantly to the growth, targeting small businesses, tradespeople, and workers facing respiratory risks. CleanSpace is set to announce detailed, audited full year FY24 results on 27 August 2024, and the Company remains committed to its core objective of ongoing 30% annual revenue growth.